Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | ubiquitin specific peptidase 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | MH1 domain containing protein | 0.001 | 0.0316 | 0.0316 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.5122 | 0.5122 |
Brugia malayi | RNA binding protein | 0.0076 | 0.5122 | 0.5122 |
Loa Loa (eye worm) | Smad1 | 0.001 | 0.0316 | 0.0316 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5122 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.5122 | 1 |
Brugia malayi | Smad1 | 0.001 | 0.0316 | 0.0316 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 1 | 1 |
Brugia malayi | MH2 domain containing protein | 0.001 | 0.0316 | 0.0316 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5122 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5122 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.5122 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5122 | 1 |
Brugia malayi | MH2 domain containing protein | 0.001 | 0.0316 | 0.0316 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.5122 | 0.5122 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.5122 | 0.5122 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5122 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.001 | 0.0316 | 0.0316 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.5122 | 0.5122 |
Loa Loa (eye worm) | MH1 domain-containing protein | 0.001 | 0.0316 | 0.0316 |
Brugia malayi | MH1 domain containing protein | 0.001 | 0.0316 | 0.0316 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.5122 | 0.5122 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. Inhibitors of USP1/UAF1: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 15.8489 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (binding) | = 44.6684 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.